Events

2012 JP Morgan Healthcare Reception

January 9, 2012

Press Club , San Francisco, California

Summary

Goodwin Procter's Life Sciences Practice will host its annual reception in conjunction with the JP Morgan Healthcare Conference in San Francisco, CA. The reception is expected to draw nearly 500 life sciences industry executives and investors.

Related Content

Life Sciences Perspectives
September 15, 2023
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions
Big Molecule Watch
September 15, 2023
Generic and Biosimilar Drugs Save $408B For America’s Patients and Healthcare System in 2022
Life Sciences Perspectives
September 15, 2023
UK’s Medicines Regulator Announces Guidance on the New International Recognition Procedure for the Approval of New Medicines from 1 January 2024
Alert
September 15, 2023
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions
Big Molecule Watch
September 14, 2023
Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al.
Life Sciences Perspectives
September 14, 2023
PropSci Perspectives: Breakthrough Properties
Alert
September 14, 2023
Sunset on (some) Stamp Taxes: HMRC confirms 1.5% charge on issuance and capital raising transfers to depositary receipt and clearance systems will not apply
Big Molecule Watch
September 13, 2023
Sandoz Receives FDA Approval for TYRUKO® (natalizumab-sztn), the First and Only FDA-Approved Biosimilar for Relapsing Forms of Multiple Sclerosis

2012 JP Morgan Healthcare Reception

Summary

Related Content

Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions

Generic and Biosimilar Drugs Save $408B For America’s Patients and Healthcare System in 2022

UK’s Medicines Regulator Announces Guidance on the New International Recognition Procedure for the Approval of New Medicines from 1 January 2024

Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions

Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al.

PropSci Perspectives: Breakthrough Properties

Sunset on (some) Stamp Taxes: HMRC confirms 1.5% charge on issuance and capital raising transfers to depositary receipt and clearance systems will not apply

Sandoz Receives FDA Approval for TYRUKO® (natalizumab-sztn), the First and Only FDA-Approved Biosimilar for Relapsing Forms of Multiple Sclerosis

Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al.

Generate:Biomedicines Completes $273 Million Series C

Lauxera Capital Partners Invests €17 Million in BioLamina

Magenta Therapeutics Completes Merger With Dianthus Therapeutics

Andreessen Horowitz-Backed Startup Health IQ Files For Bankruptcy (Forbes)

Seagen and Nurix Enter Into Strategic Collaboration for $60 Million Upfront and up to $3.4 Billion in Milestones to Develop New Class of Cancer Drugs

Goodwin Lawyers and Practices Honored at the LMG Life Sciences Americas Awards 2023

Goodwin Secures New Philadelphia Lease, Marking Its Permanent Entry Into the City (Law.com)

Life Sciences